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CObjectives: 1) To develop both English and Chinese versions of the
descriptions of health states describing different stages of breast can-
cer and different adverse effects related to tamoxifen and aromatase
inhibitors for breast cancer and 2) to elicit individuals’ preferences for
these health states from a group of oncology nurses.Methods: Twenty
ypothetical health states and their descriptions were developed on
he basis of literature review and oncology expert panel reviews.
ealth state utilities were obtained from 20 oncology nurses by using
he visual analogue scale and standard gamble methods. After recali-
ration, the adjusted utility scores were on a scale of 0 (dead) and 1
perfect health). Results: The health states developed represented dif-
erent disease stages and the presence and type of treatment side ef-
ects in breast cancer. For each health state, various general health-
elated quality-of-life domains, such as pain/discomfort and ability to
ork, were included in the descriptions, along with a state-specific O
e no
nt of
al So
oi:10.1016/j.vhri.2012.03.009escription. The mean utility score of respondents’ “current health”
as greater than 0.9, while mean adjusted visual analogue scale–d-
rived utility scores ranged from 0.256 to 0.860 and median adjusted
tandard gamble–derived utility scores ranged from 0.284 to 0.673.
mong the side effects evaluated in the “no recurrence” health state,
schemic cerebrovascular events, pulmonary embolism, and spine
racture had the greatest utility detriment. Conclusions: The study
esults indicate the value that individuals place on the avoidance of
isease progression and the side effects of hormonal therapies in
reast cancer. The health state descriptions developed can be used in
uture research to obtain society’s utilities for use in a cost-utility
nalysis.
eywords: breast cancer, standard gamble, utility, VAS.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Breast cancer is one of the world’s leading malignancies, and
billions of dollars are spent each year on its treatment [1–3].
pproximately two-third of all breast cancer patients are diag-
osed with hormone receptor (HR) positive breast cancer [4].
ence, endocrine therapy, along with other treatment strate-
ies such as surgery and chemotherapy, is one of the main
reatment modalities used in patients with early stage HR pos-
tive breast cancer. For the past few decades, tamoxifen has
een advocated as the gold standard of hormone treatment.
ore recently, for postmenopausal HR positive breast cancer
atients, third-generation aromatase inhibitors such as anas-
rozole can serve as an alternative treatment option. In choos-
ng the most appropriate therapy for postmenopausal HR posi-
ive breast cancer, in addition to effectiveness, factors such as
he cost and adverse effect profile of hormonal agents and pa-
ients’ health-related quality of life (HRQOL) are important and
eed to be carefully considered.
One way to incorporate these multiple factors into an eco-
omic evaluation is through cost-utility analysis, which com-
ares the cost per quality-adjusted life-year between different
reatment strategies. As an essential component of cost-utility
Conflicts of interest: The authors have indicated that they hav
* Address correspondence to: Yu Ko, Faculty of Science, Departme
rive 4, Singapore 117543.
E-mail: phakyn@nus.edu.sg.
212-1099/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.analysis, utility scores can be obtained by eliciting individual
preferences for health states or outcomes by using direct valu-
ation methods such as the standard gamble (SG), time trade-off,
or visual analogue scale (VAS). Utilities can also be obtained
indirectly by mapping the scores from a disease-specific HRQOL
measure, which are more sensitive than generic ones but do not
have utility scoring systems, onto a preference-based generic
measure such as the EuroQol five-dimensional questionnaire.
Currently, utility data that reflect the preferences of the com-
munity for breast cancer–related health states are not available
in Singapore.
Because there is no appropriate disease-specific HRQOL mea-
sure that can be used for all the health states assessed and because
Singapore-specific population-based values for the EuroQol five-
dimensional questionnaire are not available, the direct valuation
approach was adopted in this study. We aimed to develop both
English and Chinese versions of the descriptions of health states
describing different stages of breast cancer (no recurrence, local
recurrence, distant recurrence) and of different adverse effects
related to hormonal therapies for breast cancer, specifically ta-
moxifen and aromatase inhibitors. In addition, the preferences for
each of these health states were elicited from a group of oncology
nurses.
conflicts of interest with regard to the content of this article.
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Development of health states
To facilitate the development of the first draft of the health states,
a targeted literature review was conducted to identify the adverse
effect profiles of hormonal therapies and their impact on various
HRQOL aspects. Validation of the health state descriptions was
conducted by a group of experts comprising breast oncologists and
experienced oncology nurses.
Literature review
After the literature review, the following adverse effects resulting
from adjuvant hormone therapy were identified and included for
evaluation: fractures, vaginal bleeding, venous thromboembo-
lism, cataracts, ischemic cerebrovascular events, musculoskeletal
disorders, hot flushes, and endometrial cancer, which are all sig-
nificant adverse effects of anastrozole and tamoxifen reported in
the Arimidex, Tamoxifen, Alone or in Combination trial [5,6]. Val-
idated HRQOL instruments, namely, the European Organisation
for Research and Treatment of Cancer breast cancer-specific and
the Functional Assessment of Cancer Therapy-Breast quality-of-
life questionnaire were used as references [7,8] in description de-
velopment. Efforts were made to ensure that both the pertinent
characteristics and the degree of detriment that patients may ex-
perience during their course of cancer therapy were accurately
incorporated into the respective health state descriptions.
Health state description validation
The drafted health state descriptions underwent content valida-
tion by an expert panel, which consisted of three breast cancer
oncologists and four oncology nurses who had at least 2 years of
experience in oncology. The health state descriptions were re-
viewed and modified to ensure their accuracy with regard to
symptoms, patients’ feelings, and the level of detriment in each
HRQOL aspect included.
No major amendments were required, and it was generally
agreed that the drafted health state descriptions were compre-
hensive. Feedback from oncologists was minor and led to minor
modifications of some descriptions for clarity. An additional
domain on sleep was suggested by the nurses, and upon further
literature review, this domain was added to the final health
state descriptions. A second round of validation with the same
expert panel was conducted, and then the health state descrip-
tions were finalized.
Development of the Chinese version of the health state
descriptions
A Chinese version of the health state descriptions was developed
through forward and backward translation. The forward transla-
tion was done by the study investigators (all were bilingual and
two had research experience in translation), and back translation
was performed by a bilingual PhD pharmacy student who did not
see the original English version. After the back translation, the
original and back-translated health state descriptions were com-
pared, discrepancies were identified, and the Chinese translated
version was modified accordingly. Several iterations of the process
occurred before no difference was considered major by the study
investigators.
Health state utility measurement
Participants
A pilot study was conducted with two pharmacy PhD students and
one research assistant to identify any potential problems or fur-ther clarification needed in interview instruments and proce-
dures. No issues arose from the pilot study; therefore, no revision
was made.
The main study was conducted at the National Cancer Centre
Singapore, the largest ambulatory cancer center in Singapore that
treats approximately 70% of all cancer patients. This study was
approved by the Singhealth Centralized Institutional Review
Board. Face-to-face interviews of oncology nurses were conducted
by a trained research assistant in November 2010. Inclusion crite-
ria for participants were 1) 21 years of age or older, 2) able to com-
prehend either English or Mandarin, and 3) a minimum of 2 years
of experience in oncology. All respondents received a nominal fee
of S $50 as compensation for study participation.
Utility measurement procedures
In the interview, respondents were first required to complete a
sociodemographic questionnaire and were then instructed in the
VAS and SG procedures [9] to measure their preference for the
“dead” state, current health, and each of the 20 hypothetical
health states of breast cancer.
The descriptions for each health state were presented to the
respondents on a laminated card. The cards were labeled with a
letter of the alphabet on the back and no headings were provided
to denote what the health states were. Respondents were asked to
read and comprehend all the health state cards. The trained inter-
viewer explained to the respondents about the different colored
text on the cards and their respective meanings. Text in dark pur-
ple presented aspects of health that were specific to that particular
health state. In contrast, text in orange and black presented the
common aspects of health in most health states, but the level of
detriment in these aspects could differ among different health
states. After explanation, the respondents were asked to rank the
health states provided in the descending order according to their
preferences along with a VAS (i.e., feeling thermometer) anchored
by the health state they considered the worst at the bottom (0
point) and perfect health at the top (100 points). Respondents were
then asked to give all the other health states a value between 0 and
100. If respondents were unable to differentiate between two
health states, that is, if they felt that two health states were sim-
ilar, the two could be given the same value.
With the SG, to aid in understanding, respondents were shown
a color schematic diagram on a computer screen. For each health
state under evaluation, the respondents were asked to choose be-
tween three options [10]: 1) living in that particular health state
with certainty for the rest of their lives, 2) having a 50-50 chance of
living in perfect health or in the worst health state (HSw), and 3)
determining that the first two choices were equal. Once the re-
spondent had made an initial decision, the chance probability (p)
was varied systematically in increments of 5% until the respon-
dent switched between the first two options or selected option 3.
The same SG procedure was performed to obtain the utility score
for the “dead” state except that if the respondents considered be-
ing dead worst than HSw, they were asked to choose between
living in HSw or accepting a gamble between perfect health and
being dead instead. A probability wheel was used as a visual aid to
help the respondents more easily understand the probabilities
presented [11].
Statistical analysis
Demographic data were summarized with means and SDs for con-
tinuous variables and percentages for categorical variables. In the
VAS, if “dead” was placed at the 0 of the scale, the utility score for
each of the other health states was the scale value of its place-
ment. If being dead was considered better than HSw and placed at
some point between 0 (HSw) and 1 (perfect health), scale recalibra-
tion was needed. The adjusted score was equal to
y
r
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where score_dead is the scale placement of the “dead” state. After
recalibration, the adjusted scores can be conceptualized on a scale
of 0 (dead) and 1 (perfect health). Similar adjustment was per-
formed for the SG utility scores if HSw was judged to be the worst.
In the SG, however, if being dead was considered worse than HSw,
the adjusted score was equal to
SGadj  raw score  (1  raw score)sg_HSw
where sg_HSw is the probability (p), that is, the utility score, ob-
tained for HSw. Mean and median were used to summarize utility
scores derived from VAS and SG procedures. All statistical analy-
ses were conducted by using the Statistical Package for the Social
Sciences, version 18 (SPSS, Inc., Chicago, IL).
Results
Health state descriptions
Various general HRQOL domains such as pain/discomfort, life-
style, daily activities, ability to work, relationships with family
and friends, presence of optimal approach to life, problems with
memory, and future perspective in both work and personal life
were included in the health state descriptions. Different levels
of detriment in each domain were used to reflect the differences
among the health states. In addition to descriptions of general
domains, for each health state, a health state–specific descrip-
tion was also included. Examples include “You develop a blood
clot in the blood vessels of your leg(s) and it causes pain and
swelling” for health state F (no recurrence with deep vein
thrombosis) and “You develop clouding of the lens inside your
eyes, a condition called a cataract and you have difficulty read-
ing and seeing in the dark due to oral medication” for health
state H (no recurrence with cataract).
The descriptions of 20 hypothetical health states were devel-
oped (see Appendix in Supplemental Materials found at http://
dx.doi.org/10.1016/j.vhri.2012.03.009 for the English version; the
Chinese version is available upon request), including perfect
health state, HSw, 12 health states for no recurrence of breast
cancer (health states A–L), three for local recurrence (health states
M–O), and three for distant recurrence (health states P–R).
Sample characteristics
Of the 33 eligible nurses contacted at the National Cancer Centre
Singapore, 4 nurses were involved in the health state description
development and were therefore excluded from the interview re-
cruitment, three nurses were on leave, and four nurses declined to
participate. Two nurses were further excluded: one nurse did not
complete the interview and one was interviewed in Chinese. As
such, a total of 20 respondents were included in the analysis. The
average time for completion was approximately 75 minutes, rang-
ing from 45 to 95 minutes.
A summary of the respondents’ characteristics is shown in
Table 1. The majority of the respondents were women (90%), single
(50%), and Filipino (45%). Most respondents had completed univer-
sity education (70%) and had a gross household monthly income
between S $1000 and S $2999 (60%). The mean SD of age and the
ears of experience in oncology were 33.2 6.0 and 6.4 3.9 years,
espectively.
Health state utility values
Table 2 presents the mean and median of the VAS- and SG-derived
utility score for the health states assessed. Among the 20 hypo-
thetical health states, the health state with the lowest utility
scores was HSw, followed by “no recurrence with ischemic cere-brovascular events” whereas the health state with the highest util-
ity score, after excluding “perfect health,” was “no recurrence with
no side effect.” The mean utility score of “current health” was
greater than 0.9 using both VAS and SG procedures. Among the
side effects of hormonal therapy that may occur in the no recur-
rence state, the ones with the greatest utility detriment were pul-
monary embolism, spine fracture, and ischemic cerebrovascular
events.
Mean VAS raw scores ranged from 0.299 to 0.870. Thirteen re-
spondents considered HSw worse than being dead and placed
HSw at the bottom of the VAS (point 0). After recalibration, the
mean adjusted VAS-derived utility scores, which anchored by
dead (equal to 0) and perfect health (equal to 1), ranged from 0.256
to 0.860, with SDs ranging from 0.09 to 0.28. The VAS-derived util-
ity scores of the distant recurrence health states were consistently
lower than those of locoregional recurrence health states. Such a
trend, however, was not observed in SG-derived scores.
After recalibration, the mean adjusted SG scores for HSw
ranged from 39.0 to 0.6, which indicates great variation in re-
spondents’ preference for HSw and a few respondents’ strong
avoidance of HSw. Among the respondents who rated HSw worse
than being dead, three gave a probability (p) of greater than 0.5 for
“dead” and it was considerably higher than the probability they
gave for most of the other health states assessed; as a result, their
adjusted SG scores for most health states were negative values,
which also resulted in negative mean adjusted SG scores. As such,
the median, but not mean, adjusted SG scores are presented in
Table 2.
Discussion
Despite the increasing interest in and application of pharmaco-
Table 1 – Characteristics of the study sample.
Characteristics n (%)
Sex
Men 2 (10)
Women 18 (90)
Ethnicity
Filipino 9 (45)
Chinese 7 (35)
Indian 3 (15)
Malay 1 (5)
Highest education level attained
Secondary 1 (5)
Polytechnic diploma 2 (10)
University degree 14 (70)
Postgraduate degree 1 (5)
Advanced diploma in oncology 2 (10)
Marital status
Single 10 (50)
Married 9 (45)
Divorced 1 (5)
Gross household monthly income (S $)
1000–2999 12 (60)
3000–4999 6 (30)
5000 2 (10)
Designation
Staff nurse 11 (55)
Senior staff nurse 5 (25)
Nurse clinician 2 (10)
Others 2 (10)
Age (y), mean  SD 33.2  6.0
Years of experience in oncology, mean  SD 6.4  3.9economics in Asian countries, well-designed and rigorous utility
wors
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the health state descriptions developed in this study, which are
available in two language versions and include a large number of
combinations of side effects and disease stages, can be applied
and further refined in future research that aims to obtain patient
or general public utilities for various health outcomes related to
breast cancer and its treatment. The utility data obtained can be
combined with cost and clinical trial data to compare different
treatment strategies for breast cancer, which could assist clinical
decision making and, ultimately, produce the best benefits from
constrained health resources.
As expected, locoregional and distant recurrence health states
obtained lower utility scores than “no recurrence.” The side effects
ischemic cerebrovascular events, pulmonary embolism, and spine
fracture were observed to have the greatest utility detriment. The
utility values for ischemic cerebrovascular events were 0.256 (VAS
adjusted mean) and 0.289 (SG adjusted median), which were sim-
ilar to those reported in a systematic review [12]. The low utility
score of spine fracture is not surprising because it can affect not
only HRQOL but also mobility and functional independence [13],
which has a considerable impact as perceived by respondents who
are relatively young and in the midst of building up their careers.
Finally, in health states G and I, even though there is no recur-
rence of breast cancer, ischemic cerebrovascular events and pul-
monary embolism are life-threatening side effects, which could
explain their low utility scores. Interestingly, the raw utility scores
for endometrial cancer and new contralateral cancer fell between
0.443 and 0.506 in both SG and VAS. One may have expected these
health states to have received much lower values. Perhaps be-
cause respondents were oncology nurses with a mean of 6.4 years
Table 2 – Breast cancer health state utility scores.
VAS score, raw
Mean Medi
A: No recurrence with no side effect 0.870 0.90
B: No recurrence with hip fracture 0.514 0.50
C: No recurrence with wrist fracture 0.508 0.50
D: No recurrence with spine fracture 0.411 0.42
E: No recurrence with vaginal bleeding 0.725 0.77
F: No recurrence with deep vein thrombosis 0.582 0.57
G: No recurrence with pulmonary embolism 0.368 0.35
H: No recurrence with cataract 0.547 0.50
I: No recurrence with ischemic
cerebrovascular events
0.299 0.30
J: No recurrence with common side effects—
musculoskeletal disorder
0.653 0.69
K: No recurrence with common side
effects—hot flushes
0.749 0.77
L: No recurrence with endometrial cancer 0.506 0.52
M: New contralateral breast cancer 0.500 0.50
N: Locoregional recurrence with no side
effects
0.525 0.50
O: Locoregional recurrence with side
effects—general
0.506 0.52
P: Distant recurrence with no side effects 0.438 0.43
Q: Distant recurrence with side
effects—chemotherapy
0.404 0.46
R: Distant recurrence with side
effects—hormonal therapy
0.410 0.42
Worse health 0.033 0.00
Current health 0.944 0.99
SG, standard gamble; VAS, visual analogue scale.
* From the seven respondents who considered dead worse than theof experience, they may have been more accepting of these healthstates than the general public, similar to the fact that patients
often rate health states with higher values than does the general
population [14].
The SG, one of the choice-based preference methods, is con-
sidered to be the “gold standard” for utility measurement, and it
has been shown to be reliable and valid in Singapore and other
countries [15–20]. According to the National Institute for Health
and Clinical Excellence, the “reference case” dictates that health
state utility values have to be obtained via a choice-based method
[21]. As such, SG, along with the commonly used VAS, was used in
this study. Although the utility scores obtained may vary depend-
ing on the methods used [22–25], it has generally been reported
that SG usually provides higher utility scores than does VAS [17].
This trend, however, was not consistently observed in this
study. In addition, illogical responses were observed in several
nurses who valued “dead” considerably higher than most of the
other health states assessed in SG. The reason for these findings
remains unclear, but it may be partially explained by respon-
dents’ strong avoidance of HSw when compared with being
dead. Also, the cognitive ability and abstract thinking required
by SG may be demanding, and a few side effects could have been
difficult for these young nurses to relate to despite their expe-
rience in oncology.
There was only one interviewer involved in this study, and
therefore inconsistency in interview administration was kept to a
minimum. There are, however, a few limitations to this study.
First, the study sample size is small. Nevertheless, there is cur-
rently no consensus on sample size requirement for utility assess-
ment, and significant variation in sample size was seen in previ-
ous studies in oncology [26]. In addition, because of pragmatic
VAS score,
adjusted
SG score, raw SG score,
adjusted
Mean Median Mean Median Median
0.860 0.892 0.678 0.775 0.673
0.482 0.495 0.504 0.475 0.353
0.475 0.495 0.533 0.500 0.386
0.372 0.367 0.458 0.463 0.383
0.704 0.761 0.554 0.500 0.473
0.554 0.548 0.515 0.475 0.357
0.329 0.317 0.463 0.475 0.395
0.519 0.461 0.519 0.475 0.355
0.256 0.257 0.408 0.425 0.289
0.629 0.663 0.510 0.500 0.371
0.730 0.761 0.588 0.550 0.520
0.472 0.500 0.501 0.475 0.365
0.468 0.460 0.443 0.425 0.284
0.491 0.459 0.473 0.438 0.376
0.473 0.522 0.438 0.425 0.336
0.400 0.369 0.470 0.450 0.371
0.365 0.392 0.458 0.413 0.356
0.370 0.375 0.445 0.413 0.299
0.032 0.053 0.364* 0.500* 0.160
0.941 0.995 0.916 0.975 0.973
t health state.an
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literature review and expert opinions without patients’ direct in-
put. The validity of health state descriptions could have been im-
proved if patients who had experienced the health states had been
interviewed. Finally, the utilities obtained from nurses in our
study may not reflect societal preferences. It has been suggested
that utilities are best obtained from the general population and
from patients when clinical decisions are involved [12]. Previous
research has tried to investigate whether utilities would differ on
the basis of the study population, that is, patients versus general
public or health care professionals [27–30]; however, results have
been conflicting and inconclusive.
Conclusions
The study results indicate the value that individuals place on the
avoidance of disease progression and side effects of hormonal
therapies in breast cancer. The health state descriptions devel-
oped can be used in future research to obtain society’s utilities for
use in a cost-utility analysis.
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